Sarepta Therapeutics
SRPT
376 hedge funds and large institutions have $8.65B invested in Sarepta Therapeutics in 2022 Q3 according to their latest regulatory filings, with 81 funds opening new positions, 121 increasing their positions, 115 reducing their positions, and 36 closing their positions.
125% more first-time investments, than exits
New positions opened: 81 | Existing positions closed: 36
68% more call options, than puts
Call options by funds: $269M | Put options by funds: $160M
57% more capital invested
Capital invested by funds: $5.5B → $8.65B (+$3.15B)
13% more funds holding
Funds holding: 332 → 376 (+44)
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
5.48% more ownership
Funds ownership: 83.85% → 89.34% (+5.5%)
5% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 115
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$95.6M |
| 2 |
O
OrbiMed
New York
|
+$90.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$89M |
| 4 |
Two Sigma Investments
New York
|
+$76.5M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$74.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$124M |
| 2 |
Janus Henderson Group
London,
|
-$76.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$47.5M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$43.4M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$38.7M |
SRPT Hedge Fund Activity: Q3 2022 in Review
376 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2022, worth a combined $8.65B — up 57% from $5.5B a quarter earlier.
Buyers outnumbered sellers: 81 funds opened new SRPT positions and 36 closed out — a net gain of 45 holders — while 121 added to existing stakes and 115 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $95.6M. The largest seller was Sands Capital Management, cutting an estimated $124M.
- 376 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2022, up from 332 in Q2 2022.
- Funds reported $8.65B of Sarepta Therapeutics stock for Q3 2022, up 57% quarter-over-quarter.
- 81 funds opened new Sarepta Therapeutics positions in Q3 2022 and 36 closed out, a net change of +45 holders.
- The largest Sarepta Therapeutics buyer in Q3 2022 was Avidity Partners Management, an estimated $95.6M added.
- The largest Sarepta Therapeutics seller in Q3 2022 was Sands Capital Management, an estimated $124M sold.
Based on aggregated 13F filings for Q3 2022.